Big Data for outcomes and clinical research:

major advance or improvement needed

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Creation of Big Data repositories is now emphasized at virtually all research institutions and the NIH, but the number of publications describing patient outcomes from these sources appears modest.1 Why is this so; what factors limit what should be a hugely productive resource, and how can we improve the impact of this use of Big Data? Why does this issue require greater physician engagement and understanding to solve? The integration of clinical, laboratory, and financial data is required to describe disease and treatment outcomes as well as treatment value.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Roy B. Jones
Department of Stem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, Houston, TX
Amar Chahal
Chief operating officer, Velos Inc.
Dianne Reeves, MD
Retired associate director, Center for Biomedical Informatics and Information Technology, NCI
Gregory H. Jones
Resident, University of Texas School of Medicine
Charles S. Martinez
Department of Stem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, Houston, TX
Table of Contents

YOU MAY BE INTERESTED IN

Despite steady progress in reducing overall cancer mortality rates, cancer incidence in women is rising, according to the American Cancer Society’s “Cancer Statistics, 2025” report. Incidence rates in women 50-64 years of age have surpassed those in men, and rates in women under 50 are now 82% higher than their male counterparts, up from 51% higher in 2002. In 2021, for the first time, lung cancer incidence was higher in women under 65 than in men. 
Over the past five years, Cedars-Sinai Cancer has built an integrated, regional system designed to provide cancer care close to where patients live and work. This model of care, directed by an academic medical center to patients at the community level, proved to be the best possible approach to supporting patients in our 11-million-person catchment area during the worst fire disaster in California history. 
Roy B. Jones
Department of Stem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, Houston, TX
Amar Chahal
Chief operating officer, Velos Inc.
Dianne Reeves, MD
Retired associate director, Center for Biomedical Informatics and Information Technology, NCI
Gregory H. Jones
Resident, University of Texas School of Medicine
Charles S. Martinez
Department of Stem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, Houston, TX

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login